| Mako Chen, MD | |
|
7301 Rogers Ave, Fort Smith, AR 72903-4100 | |
| (479) 314-6000 | |
| Not Available |
| Full Name | Mako Chen |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 20 Years |
| Location | 7301 Rogers Ave, Fort Smith, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134433303 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | NONE (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Fort Smith | Fort smith, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Clinic Fort Smith Communities | 3870668510 | 273 |
News Archive
Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The
Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
› Verified 5 days ago
| Entity Name | Johnson Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336198555 PECOS PAC ID: 1658360284 Enrollment ID: O20040623000733 |
News Archive
Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The
Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
› Verified 5 days ago
| Entity Name | Mercy Clinic Fort Smith Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902073620 PECOS PAC ID: 3870668510 Enrollment ID: O20080814000789 |
News Archive
Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The
Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mako Chen, MD 7301 Rogers Ave, Fort Smith, AR 72903-4100 Ph: () - | Mako Chen, MD 7301 Rogers Ave, Fort Smith, AR 72903-4100 Ph: (479) 314-6000 |
News Archive
Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The
Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
› Verified 5 days ago
Cygnet A Bise, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1001 Towson Ave, Fort Smith, AR 72901 Phone: 479-478-8555 Fax: 479-478-8555 | |
Joseph E Miller, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 9001 Jenny Lind Rd Ste 3, Fort Smith, AR 72908 Phone: 479-385-9001 Fax: 479-763-1156 | |
Dr. Samuell Leyton Cabe, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 9220 Highway 71 S Ste 4, Fort Smith, AR 72916 Phone: 479-484-1100 Fax: 479-484-1105 | |
Chris Strasser, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 9101 Ra Young Jr Dr Ste 107, Fort Smith, AR 72916 Phone: 479-222-1425 | |
Dr. Bradley Mark Short, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3905 Brooken Hill Dr, Fort Smith, AR 72908 Phone: 479-646-3345 Fax: 479-646-6049 | |
Emily King, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5905 Remington Cir, Fort Smith, AR 72903 Phone: 479-452-7774 Fax: 479-452-7774 |